bio-formulation-995x60 bio-formulation-995x60

FEATURED ARTICLES

  • Pfanstiehl Sheds Ferro Corp. For Greater Investment & Growth
    Pfanstiehl Sheds Ferro Corp. For Greater Investment & Growth

    After operating under the Ferro umbrella for 13 years, Ferro Pfanstiehl Laboratories was purchased by PLI Holdings, an affiliate of Med Opportunity Partners (MEDOP). James Breckenridge, founding member of MEDOP, and Cynthis Kerker, president of Pfanstiehl, discuss why the acquisition is good news for the future growth of Pfanstiehl, and how the company's products, focus on quality, and SafeBridge certification made them a good fit with MEDOPs other strategic partners.

More Featured Articles

PRODUCTS & SERVICES

Single Use Biopharmaceutical Powder Handling Equipment

Single Use Biopharmaceutical Powder Handling Equipment

ILC Dover brings a unique history and skill set to the biopharmaceutical industry, particularly single use biopharmaceutical powder handling and containment equipment.

Supporting Advances In MAb Process Development And Manufacturing

Supporting Advances In MAb Process Development And Manufacturing

GE Healthcare is a $17 billion unit of the General Electric Company (NYSE:GE), employing more than 46 000 people worldwide.

SciLog MabTec®

SciLog MabTec®

The SciLog MabTec® is a automated high density cell culture system.

Single-Use And Ready-To-Use Biopharmaceutical Products

Single-Use And Ready-To-Use Biopharmaceutical Products

Biopharmaceutical development and manufacturing demands scalable processes that can be quickly developed and smoothly transferred to production. GE Healthcare Life Sciences’ single-use and ready-to-use technologies, ReadyToProcess™ and Xcellerex™, play a crucial role in providing the flexibility to support multi-product facilities. They deliver process time savings by removing steps such as cleaning, cleaning-validation, filter prewashing and column packing, allowing faster start-up and easier changeover between products.

More Products & Services
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.

ABOUT

Formulation

Formulation in bioresearch is directly associated with pharmaceutical research and development. It is the practice of combining different chemical substances that include the active medical drug. This combination of drug and chemicals is tweaked until they have a final medicinal formulation that can be tested and receive final approval for large-scale market use.

The object of pre-formulation and formulation is to develop a stable preparation of a specific drug that is acceptable for human consumption. All drugs, by necessity, contain other chemicals.  In order to put a drug into a capsule or tablet form it requires a variety of substances other than the drug itself. Formulation is needed to ensure that the drug will work when combined with these other substances.

It may surprise you to know that most formulations are not complete until after Phase III clinical trials are in progress or completed. All the early trials test drug stability, and drug load, which is the ratio of active drug to the total content of the actual dose.

Formulation studies address a variety of issues includinggrain size, pH (acidic or alkaline), solubility, and polymorphism (the ability of a drug to exist in more than one form like liquid and capsule).  Other items formulation addresses is taste, appearance, tablet hardness and tablet or capsule disintegration.

Another aspect of formulation is testing how humidity, temperature, oxidation, ultraviolet light or visible light affects the formulation. The formula must be stable and not degrade under all of the different environmental factors.

Formulation involves a lot of experimenting with different blends of materials and drugs, but is absolutely crucial for the development of effective, safe, stable, oral drugs, and topical ointments.